Toyota Named an Official Sponsor of the Orange Blossom Classic
June 14, 2021 14:26 ET
|
Orange Blossom Classic
Miami, FL, June 14, 2021 (GLOBE NEWSWIRE) -- The Orange Blossom Classic Committee confirmed today that Toyota Motor North America would serve as the official sponsor of the Orange Blossom Classic...
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
June 11, 2021 06:30 ET
|
Novan, Inc.
– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 – – No serious adverse events related to treatment with SB206 – – Novan intends to submit New...
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
June 10, 2021 08:30 ET
|
Novan, Inc.
– Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies – – Statistically significant, dose-dependent reduction in the...
Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health
June 07, 2021 08:30 ET
|
Novan, Inc.
– Positive in vitro results demonstrate antimicrobial effect of NVN4100 against a wide variety of bacteria and suggest a promising bactericidal mode of action – – Novel in vivo canine pyoderma model...
Novan Announces 1-for-10 Reverse Stock Split
May 25, 2021 08:00 ET
|
Novan, Inc.
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has filed a Certificate of Amendment to the Restated Certificate of...
Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:05 ET
|
Novan, Inc.
– Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating...
Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
May 03, 2021 08:30 ET
|
Novan, Inc.
– Topline data on track for readout before the end of Q2 2021 – – Currently no FDA-approved therapies for the treatment of molluscum – – Potential for NDA filing no later than Q3 2022 – DURHAM,...
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
April 22, 2021 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s previously completed Phase 3 trials of SB206...
Novan to Present at the H.C. Wainwright Global Life Sciences Conference
March 05, 2021 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of...
Novan Bolsters Commercialization Expertise with Election of Steven D. Skolsky to Board of Directors
March 02, 2021 08:30 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the election of Steven D. Skolsky to its Board of Directors. Mr. Skolsky...